PMID- 34207217
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210714
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 14
IP  - 6
DP  - 2021 Jun 18
TI  - Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from 
      Natural Sources: A Novel Approach for the Management of Diabetes.
LID - 10.3390/ph14060586 [doi]
LID - 586
AB  - Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia that is 
      predominantly caused by insulin resistance or impaired insulin secretion, along 
      with disturbances in carbohydrate, fat and protein metabolism. Various 
      therapeutic approaches have been used to treat diabetes, including improvement of 
      insulin sensitivity, inhibition of gluconeogenesis, and decreasing glucose 
      absorption from the intestines. Recently, a novel approach has emerged using 
      dipeptidyl peptidase-IV (DPP-IV) inhibitors as a possible agent for the treatment 
      of T2DM without producing any side effects, such as hypoglycemia and exhaustion 
      of pancreatic beta-cells. DPP-IV inhibitors improve hyperglycemic conditions by 
      stabilizing the postprandial level of gut hormones such as glucagon-like 
      peptide-1, and glucose-dependent insulinotropic polypeptides, which function as 
      incretins to help upregulate insulin secretion and beta-cell mass. In this review, 
      we summarized DPP-IV inhibitors and their mechanism of inhibition, activities of 
      those isolated from various natural sources, and their capacity to overcome 
      oxidative stress in disease conditions.
FAU - Singh, Anand-Krishna
AU  - Singh AK
AUID- ORCID: 0000-0002-3619-3292
AD  - Shri Vaishnav Institute of Science, Shri Vaishnav Vidyapeeth Vishwavidyalaya, 
      Indore, Madhya Pradesh 453555, India.
FAU - Yadav, Dhananjay
AU  - Yadav D
AUID- ORCID: 0000-0003-4047-7236
AD  - Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Korea.
FAU - Sharma, Neha
AU  - Sharma N
AD  - School of Life Sciences, Devi Ahilya University, Indore, Madhya Pradesh 452001, 
      India.
FAU - Jin, Jun-O
AU  - Jin JO
AUID- ORCID: 0000-0003-4216-8111
AD  - Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Korea.
AD  - Research Institute of Cell Culture, Yeungnam University, Gyeongsan 38541, Korea.
LA  - eng
GR  - NRF-2019R1G1A1008566,NRF-2018R1A6A1A03023584/National Research Foundation of 
      Korea/
PT  - Journal Article
PT  - Review
DEP - 20210618
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC8234173
OTO - NOTNLM
OT  - antioxidant
OT  - dipeptidyl peptidase-IV
OT  - glucagon-like peptide-1
OT  - hyperglycemia
OT  - incretin
COIS- The authors declare that there is no conflict of interest regarding the 
      publication of this paper.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/03 06:01
PMCR- 2021/06/18
CRDT- 2021/07/02 01:30
PHST- 2021/03/22 00:00 [received]
PHST- 2021/06/08 00:00 [revised]
PHST- 2021/06/13 00:00 [accepted]
PHST- 2021/07/02 01:30 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/03 06:01 [medline]
PHST- 2021/06/18 00:00 [pmc-release]
AID - ph14060586 [pii]
AID - pharmaceuticals-14-00586 [pii]
AID - 10.3390/ph14060586 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2021 Jun 18;14(6):586. doi: 10.3390/ph14060586.